Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 5:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 227 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Intravenous fluid administration Clear all
Terminated Phase 2 Interventional Results available

Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome

NCT02098993
View directory record Official record
Conditions
Acute Chest Syndrome, Sickle Cell Disease
Interventions
Unfractionated heparin
Drug
Lead sponsor
Craig Seaman
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Sep 6, 2026, 5:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants

NCT04468958
View directory record Official record
Conditions
COVID-19, SARS-CoV2
Interventions
SAB-185, Normal saline
Biological · Other
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
3
States / cities
Wichita, Kansas • Syracuse, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Sep 6, 2026, 5:25 AM EDT
Completed Phase 2 Interventional Results available

COMbination of Bipolar Androgen Therapy and Nivolumab

NCT03554317
View directory record Official record
Conditions
Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer
Interventions
Testosterone cypionate, Nivolumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
San Francisco, California • Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Sep 6, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Results available

Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study)

NCT00608491
View directory record Official record
Conditions
Heart Failure
Interventions
Stepped pharmacologic care, Ultrafiltration
Drug · Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
8
States / cities
Phoenix, Arizona • Atlanta, Georgia • Minneapolis, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Sep 6, 2026, 5:25 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus

NCT00381810
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Rituximab, Methylprednisolone, Acetaminophen, Diphenhydramine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
16 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
11
States / cities
Paradise Valley, Arizona • San Leandro, California • Boise, Idaho + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Sep 6, 2026, 5:25 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Medical and Surgical Treatment of Uncomplicated Acute Appendicitis in Children

NCT02991937
View directory record Official record
Conditions
Appendicitis
Interventions
Piperacillin/Tazobactam, Surgical Treatment
Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
6 Years to 17 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Sep 6, 2026, 5:25 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Capsaicin Cream as an Adjunctive Therapy for Nausea and Vomiting of Pregnancy

NCT05098067
View directory record Official record
Conditions
Hyperemesis Gravidarum, Nausea Gravidarum, Vomiting of Pregnancy
Interventions
Capsaicin Topical Cream, Metoclopramide, Ondansetron, Lactated Ringers, Intravenous
Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Sep 6, 2026, 5:25 AM EDT
Completed Phase 4 Interventional Results available

Subcutaneous Rehydration Compared to Intravenous Rehydration

NCT00773175
View directory record Official record
Conditions
Dehydration
Interventions
recombinant human hyaluronidase
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
30 Days to 10 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
25
States / cities
Hartford, Connecticut • Orlando, Florida • Tampa, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Sep 6, 2026, 5:25 AM EDT
Active, not recruiting Phase 1 Interventional

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

NCT03025256
View directory record Official record
Conditions
Acral Lentiginous Melanoma, Central Nervous System Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Leptomeningeal Neoplasm, Melanocytoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Metastatic Mucosal Melanoma, Metastatic Uveal Melanoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Lumbar Puncture, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography
Procedure · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 6, 2026, 5:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparison of AccuCath IV Catheter and Conventional IV Catheter in Interventional Radiology

NCT01940354
View directory record Official record
Conditions
Vascular Access Complications
Interventions
AccuCath IV Catheter System, Conventional IV Catheter System
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years to 89 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Sep 6, 2026, 5:25 AM EDT
Recruiting Phase 3 Interventional

A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)

NCT07555483
View directory record Official record
Conditions
Alpha 1 Antitrypsin Deficiency
Interventions
Alpha-1 15%, Liquid Alpha1-PI
Drug · Other
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 6, 2026, 5:25 AM EDT
Completed Phase 3 Interventional

Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection

NCT00035425
View directory record Official record
Conditions
Febrile Neutropenia
Interventions
linezolid, vancomycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
16
States / cities
Los Angeles, California • Springfield, Illinois • The Bronx, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2009 · Synced Sep 6, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Results available

Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy

NCT00666263
View directory record Official record
Conditions
Multifocal Motor Neuropathy
Interventions
Immune Globulin Intravenous (human), 10%, 0.25% human albumin solution (Placebo)
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
12
States / cities
Los Angeles, California • Stanford, California • Centennial, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 6, 2026, 5:25 AM EDT
Recruiting Not applicable Interventional

Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants

NCT05547165
View directory record Official record
Conditions
Ductus Arteriosus, Patent
Interventions
Percutaneous Patent Ductus Arteriosus Closure (PPC), Responsive Management Intervention, Echocardiogram, cardiac
Device · Combination Product · Diagnostic Test
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
7 Days to 32 Days
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 6, 2026, 5:25 AM EDT
Completed Phase 1 Interventional

Study of GO-203-2C Given Intravenously in Patients With Advanced Solid Tumors Including Lymphomas

NCT01279603
View directory record Official record
Conditions
Solid Tumors
Interventions
GO-203-2c
Drug
Lead sponsor
Genus Oncology, LLC
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Scottsdale, Arizona • Los Angeles, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Sep 6, 2026, 5:25 AM EDT
Recruiting No phase listed Observational

Value of PET/MR Enterography in the Assessment of Crohn's Disease Using a Collagen-binding Radiotracer.

NCT06252493
View directory record Official record
Conditions
Crohn Disease
Interventions
Radiotracer Injection, Contrast Media, Magnetic Resonance, Blood Draw, Glucagon, Imaging, Oral contrast media application
Drug · Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 6, 2026, 5:25 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Peramivir in Children With Influenza

NCT01063933
View directory record Official record
Conditions
Influenza
Interventions
Peramivir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2012
U.S. locations
29
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Orange, California + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2011 · Synced Sep 6, 2026, 5:25 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

NCT04504825
View directory record Official record
Conditions
AL Amyloidosis
Interventions
CAEL-101, Placebo, cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen
Drug · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
26
States / cities
Duarte, California • Palo Alto, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 6, 2026, 5:25 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)

NCT04547140
View directory record Official record
Conditions
COVID-19
Interventions
Liquid Alpha1-Proteinase Inhibitor (Human), Placebo, Standard Medical Treatment
Biological · Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Sep 6, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Results available

Randomized Control Trial of Fluid Therapy for Pediatric Diabetic Ketoacidosis

NCT01365793
View directory record Official record
Conditions
Cerebral Edema, Diabetic Ketoacidosis
Interventions
0.45% saline replacement fluid, 0.9% saline replacement fluid, 0.45% saline intravenous fluid, 0.9% saline Intravenous fluid
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
Up to 17 Years
Enrollment
1,389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
13
States / cities
Sacramento, California • Aurora, Colorado • Wilmington, Delaware + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2018 · Synced Sep 6, 2026, 5:25 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Enhanced Recovery Pathway for Endoscopy

NCT04983498
View directory record Official record
Conditions
Enhanced Recovery Pathway, Endoscopy
Interventions
Ondansetron 4 MG, Lactated Ringers, Intravenous, Early Mobilization, Early PO Intake
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Sep 6, 2026, 5:25 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Randomized Controlled Trial to Test the Effects Oxytocin and Vibration Have on Heat Pain Threshold After UV-B Burn

NCT06651476
View directory record Official record
Conditions
Sunburn
Interventions
oxytocin, placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 6, 2026, 5:25 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients

NCT04497389
View directory record Official record
Conditions
SARS CoV-2
Interventions
Human Amniotic Fluid
Biological
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Sep 6, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab

NCT02747043
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
ABP 798, Rituximab
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Encinitas, California • Mount Sterling, Kentucky • Billings, Montana + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2022 · Synced Sep 6, 2026, 5:25 AM EDT